重庆华森制药股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 （一）重庆华森制药股份有限公司（以下简称"公司"或"华森制药"）第 三届董事会第十七次会议（以下简称"本次会议"）通知以书面及电话方式于 （二）本次会议于 2025 年 5 月 13 日 13 时 30 分在公司三楼会议室以现场表 决的方式召开。 （三）本次会议应到董事 9 名，实际出席并表决的董事 9 名。董事游洪涛、 刘小英、王瑛、游雪丹、游苑逸（Yuanyi You）、梁燕、李嘉明、杜守颖、秦少 容均为现场出席会议并进行表决，公司全体高级管理人员列席会议。 （四）公司董事长游洪涛先生主持会议。 （五）本次会议的通知、召集和召开符合《中华人民共和国公司法》等法律、 行政法规、部门规章、规范性文件及《重庆华森制药股份有限公司章程》的有关 规定。 二、董事会会议审议情况 证券代码：002907 证券简称：华森制药 公告编号：2025-041 本次成都奥睿药业有限公司（下称"奥睿药业"）股权变更完成后，公司及 其控股子公司重庆华森英诺生物科技有限公司（下称"华森英诺 ...

Transaction Overview - Company and its wholly-owned subsidiary, Chongqing Huason Yino Biotechnology Co., Ltd., will acquire 37.3619% equity of Chengdu Aorui Pharmaceutical Co., Ltd. to enhance innovation drug R&D capabilities and accelerate transformation [1][2] - After the transaction, the company and Huason Yino will hold a combined 66% equity in Aorui Pharmaceutical, which will be included in the company's consolidated financial statements [1][3] Background of the Transaction - The company participated as an angel investor in Aorui Pharmaceutical in June 2020, investing 30 million RMB at a capital increase price of 4.6146 RMB per registered capital [2] - Aorui Pharmaceutical has faced operational difficulties since 2023, triggering buyback clauses due to failure to submit clinical trial applications by the deadline [3][4] Financial and Operational Status of Aorui Pharmaceutical - Aorui Pharmaceutical reported a net loss of approximately 24.89 million RMB for the year ending December 31, 2024, with current liabilities exceeding current assets by about 11.08 million RMB [9] - The company’s total assets were approximately 26.76 million RMB, and net assets were about 12.98 million RMB as of December 31, 2024 [9] Valuation and Equity Transfer - The valuation report indicated that the book value of Aorui Pharmaceutical's equity was 12.98 million RMB, while the assessed value was 98.39 million RMB, reflecting a significant increase of 658.12% [10] - The equity transfer price is based on this valuation, ensuring fair pricing and protection of the company's and shareholders' interests [10] Strategic Importance of Aorui Pharmaceutical - Aorui Pharmaceutical's core asset, ORIC-1940, has received clinical approval and is positioned to address a critical medical need in treating secondary hemophagocytic lymphohistiocytosis (HLH) [19][20] - The integration of Aorui Pharmaceutical into the company's innovation drug segment is expected to enhance the overall R&D pipeline and success rates in drug development [20] Guarantee and Risk Management - The company will provide a guarantee of up to 26 million RMB for Huason Yino's obligations under the equity transfer agreement, with a three-year term [21][24] - The board believes that the financial condition of Huason Yino is stable, and the risks associated with the guarantee are manageable [24] Board Approval and Compliance - The transaction was approved by the board with unanimous consent, and it does not constitute a related party transaction or a major asset restructuring as defined by regulations [2][3]

股东全部权益价值 资产评估报告 本报告依据中国资产评估准则编制 重庆华森制药股份有限公司拟进行对外投资事宜 所涉及的成都奥睿药业有限公司 中评正信评报字[2025]133号 共1册,第1册 中国资产评估协会 资产评估业务报告备案回执 | 报告编码: | 111160004202500206 | | | | --- | --- | --- | --- | | 合同编号: | 2025-155 | | | | 报告类型: | 非法定评估业务资产评估报告 | | | | 报告文号: | 中评正信评报字[2025]133号 | | | | 重庆华森制药股份有限公司拟进行对外投资事宜所涉及的成都奥 | 报告名称: | 睿药业有限公司股东全部权益价值资产评估报告 | | | 评估结论: | 98.385.900 NAFF A FI | | | | 评估报告日: | 2025年04月30日 | | | | 评估机构名称: | 北京中调西靠资产评估有限公司 | | | | 申时钟 | 正式会员 | 编号: 11001441 | 签名人员: | | 贺成丽 | (资产评估师) | 见习会员 | 编号:41130086 | | ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码：002907 证券简称：华森制药 公告编号：2025-040 重庆华森制药股份有限公司 关于公司全资子公司受让成都奥睿药业有限公司股 权及公司为全资子公司提供对外担保的公告 一、交易事项 （一）交易概述 为了整合与补充创新药研发管线，进一步加强重庆华森制药股份有限公司 （以下简称"华森制药"或"公司"）创新药研发能力，提高华森制药创新药研 发成功的可能性，加速华森制药转型升级，公司及其下属全资子公司重庆华森英 诺生物科技有限公司（以下简称"华森英诺"）与成都奥睿药业有限公司（以下 简称"奥睿药业"或"目标公司"）的现有股东杨胜勇、黄奇、深圳市中小担创 业投资有限公司、深圳市人才创新创业三号三期股权投资基金合伙企业（有限合 伙）、深圳市中小担天使一期创业投资合伙企业（有限合伙）及成都地奥九泓制 药厂签署《股权变更协议》，华森英诺将无偿受让奥睿药业 37.3619%股权（以 下简称"本次股权转让"或"本次交易"）作为公司及华森英诺承担奥睿药业的 历史交易文件中杨胜勇、黄奇对深圳市中小担创业投资有限公司、深圳 ...

（三）本次会议应到董事 9 名，实际出席并表决的董事 9 名。董事游洪涛、 刘小英、王瑛、游雪丹、游苑逸（Yuanyi You）、梁燕、李嘉明、杜守颖、秦少 容均为现场出席会议并进行表决，公司全体高级管理人员列席会议。 （四）公司董事长游洪涛先生主持会议。 （五）本次会议的通知、召集和召开符合《中华人民共和国公司法》等法律、 行政法规、部门规章、规范性文件及《重庆华森制药股份有限公司章程》的有关 规定。 证券代码：002907 证券简称：华森制药 公告编号：2025-041 重庆华森制药股份有限公司 第三届董事会第十七次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 （一）重庆华森制药股份有限公司（以下简称"公司"或"华森制药"）第 三届董事会第十七次会议（以下简称"本次会议"）通知以书面及电话方式于 2025 年 5 月 8 日向各位董事发出。 （二）本次会议于 2025 年 5 月 13 日 13 时 30 分在公司三楼会议室以现场表 决的方式召开。 二、董事会会议审议情况 （一）审议通过《关于公司全资子公司受让成都奥 ...

Group 1: Company Performance and Strategy - The company emphasizes compliance with information disclosure while discussing operational performance, product layout, market development, and production management [2] - The impact of centralized procurement (集采) is significant on existing products but limited on new varieties; the company aims to explore diversified development in advantageous areas [3] - The company has established a "three-three-three" pipeline structure for R&D, focusing on new product launches to drive revenue growth [3] Group 2: R&D and Innovation - The company is advancing four innovative drug R&D pipelines targeting various cancers, with 17 patent applications filed by the end of 2024 [4] - The first global innovative drug project HSN003 was showcased at the AACR annual meeting in 2024, marking a step towards international integration [4] - The company plans to continue R&D investments while managing risks to inject vitality into its development [5] Group 3: Sales and Market Expansion - The sales strategy remains focused on public hospitals, which account for approximately 70% of the market, while also expanding into grassroots hospitals, private hospitals, retail pharmacies, and e-commerce platforms [6] - The company has made significant strides in overseas markets, with FDA approvals for production facilities and products, enhancing its international presence [7] Group 4: Traditional Chinese Medicine (TCM) Performance - Revenue from five key TCM products grew by 21.71% in 2024, with notable increases in specific products such as 甘桔冰梅片 (29.97%) and 六味安神胶囊 (23.38%) [8] - The company is focusing on the technical market promotion and access of its key TCM products, especially in non-grade public hospital channels [8] Group 5: Cost Management and Procurement Strategy - The company anticipates that the high costs of raw materials for TCM will not persist long-term and is conducting market research to monitor trends [10] - A flexible procurement strategy is being implemented to manage costs and ensure supply chain stability, including small batch purchases to mitigate inventory risks [11]

长江商报奔腾新闻记者 徐佳 此后在2024年11月至2025年2月期间，成都地建合计减持华森制药1252.78万股，占公司总股本的3%。 按照减持最低价格计算，本轮减持中，成都地建累计套现1.47亿元。 5月13日晚间，华森制药披露控股股东减持计划。公司控股股东成都地方建筑机械化工程有限公司（以 下简称"成都地建"）计划在公告披露之日起15个交易日后的3个月内，通过集中竞价、大宗交易方式合 计减持公司股份不超过1252.79万股，即不超过公司总股本的3%。 同时，华森制药的高管彭晓燕也计划在同样的时间段内，减持华森制药股份不超过4375股，即不超过公 司总股本的0.0010%。 目前，成都地建、彭晓燕分别直接持有华森制药1.76亿股、1.75万股，占公司总股本的比例为 42.0435%、0.0042%。 对于本次减持华森制药的目的，成都地建、彭晓燕方面称主要是因经营发展需要、个人资金需求，减持 股份来源分别为公司首次公开发行前发行的股份以及公司2019年限制性股票激励计划所取得的股份。 长江商报奔腾新闻记者注意到，这也是华森制药在近一年时间内第二次遭到控股股东减持。 2024年10月，华森制药曾披露，成都地建 ...

Core Viewpoint - The announcement details the share reduction plan by the controlling shareholder Chengdu Local Construction Machinery Engineering Co., Ltd. and senior management personnel, indicating their intention to sell a total of up to 12,527,889 shares, which is approximately 3% of the company's total share capital, over a specified period [1][3][9] Shareholder Information - Chengdu Local Construction Machinery Engineering Co., Ltd. holds 175,572,175 shares, accounting for 42.04% of the company's total share capital [1] - Senior management personnel, specifically Ms. Peng Xiaoyan, holds 17,500 shares, representing 0.0042% of the total share capital [1] Share Reduction Plan Details - Chengdu Local Construction plans to reduce its holdings by up to 4,175,963 shares (1% of total shares) through centralized bidding and up to 8,351,926 shares (2% of total shares) through block trading, totaling a maximum of 12,527,889 shares [1][3] - Ms. Peng Xiaoyan intends to reduce her holdings by no more than 4,375 shares, which is less than 0.01% of the total share capital [2][3] Reduction Timing and Method - The reduction period is set from June 6, 2025, to September 5, 2025, starting 15 trading days after the announcement [1][3] - The reduction will be executed through centralized bidding and block trading, with the price determined by market conditions [2][5] Compliance and Commitments - Chengdu Local Construction has committed to adhere to relevant regulations regarding share reduction and has previously complied with lock-up commitments [6][7][8] - Ms. Peng Xiaoyan has also followed the regulations regarding share transfer during her tenure and after leaving the company [8] Risk and Impact Assessment - The company emphasizes that the share reduction plan will not lead to a change in control or significantly impact the company's governance structure or ongoing operations [9]

证券代码：002907 证券简称：华森制药 公告编号：2025-039 重庆华森制药股份有限公司 关于公司控股股东及高级管理人员减持股份预披露 的公告 | 股东名称 | 持股数量（股） | 占公司总股本比例（%） | | --- | --- | --- | | 成都地建 | 175,572,175 | 42.0435 | | 彭晓燕 | 17,500 | 0.0042 | 二、本次股份减持计划的主要内容 （一）成都地建 、 减持股份数量 ： 拟减持公司股份数量不超过12,527,889股（含）（若此期间 （二）彭晓燕 公司控股股东成都地方建筑机械化工程有限公司、高级管理人员彭 晓燕女士保证向本公司提供的信息内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信 息一致。 特别提示： 重庆华森制药股份有限公司（以下简称"公司"）于近日收到公司控股股东成 都地方建筑机械化工程有限公司（以下简称"成都地建"）和高级管理人员彭晓燕 女士发来的《关于计划减持公司股份的告知函》。 持有公司175,572,175股份的控股股东成都地建计划自本公告披露之日起1 ...

华森制药（002907）公告，控股股东成都地建计划减持不超过1252.79万股，即不超过公司总股本的 3%。高管彭晓燕计划减持不超过4375股，即不超过公司总股本的0.0010%。 ...